Thymoma-associated myasthenia gravis: On the search for a pathogen signature

Journal of Autoimmunity

Volumn 52, Issue , 2014, Pages 29-35

  Cufi, Perrine ^a,b,c,d   Soussan, Patrick ^e,f   Truffault, Frédérique ^a,b,c,d   Fetouchi, Rachid ^e,f   Robinet, Marieke ^a,b,c,d   Fadel, Elie ^g   Berrih Aknin, Sonia ^a,b,c,d   Le Panse, Rozen ^a,b,c,d  

^a Sorbonne Université   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d AIM   (France)

^e HÔPITAL TENON   (France)

^f INSERM   (France)

^g CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

Innate immunity; Interferon type I; Myasthenia gravis; Thymoma; Toll like receptors; Virus

Indexed keywords

ALPHA2 INTERFERON; ALPHA8 INTERFERON; BETA INTERFERON; DNA; DOUBLE STRANDED RNA; INTERFERON; OMEGA INTERFERON; PROTEIN KINASE R; PROTEIN P16; PROTEIN P53; RNA HELICASE; TOLL LIKE RECEPTOR 3; UNCLASSIFIED DRUG; VIRUS DNA; AUTOANTIBODY; CHOLINERGIC RECEPTOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; VIRUS ANTIBODY; INTERFERON ALPHA 8; INTERFERON OMEGA; INTERFERON TYPE 1 ANTIBODY; NEUTRALIZING ANTIBODY; RETINOIC ACID INDUCIBLE PROTEIN I;

ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; INNATE IMMUNITY; MYASTHENIA GRAVIS; PAPILLOMAVIRUS INFECTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; THYMOMA; UPREGULATION; VIRAL GENETICS; VIRUS INFECTION; WART VIRUS; ALPHAPAPILLOMAVIRUS; CELL CULTURE; COMPLICATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; THYMUS NEOPLASMS; YOUNG ADULT; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; ALPHAPAPILLOMAVIRUS; ANTIBODIES, VIRAL; AUTOANTIBODIES; CELLS, CULTURED; CHILD, PRESCHOOL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; INFANT; INFANT, NEWBORN; INTERFERON TYPE I; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PAPILLOMAVIRUS INFECTIONS; RECEPTORS, CHOLINERGIC; THYMOMA; THYMUS NEOPLASMS; YOUNG ADULT;

EID: 84904314341     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2013.12.018     Document Type: Article

References (49)

1. Meriggioli M.N. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci 2009, 26:94-108.
2. Vrolix K., Fraussen J., Molenaar P.C., Losen M., Somers V., Stinissen P., et al. The auto-antigen repertoire in myasthenia gravis. Autoimmunity 2010, 43:380-400.
3. Le Panse R., Bismuth J., Cizeron-Clairac G., Weiss J.M., Cufi P., Dartevelle P., et al. Thymic remodeling associated with hyperplasia in myasthenia gravis. Autoimmunity 2010, 43:1-12.
4. Marx A., Pfister F., Schalke B., Saruhan-Direskeneli G., Melms A., Strobel P. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes. Autoimmun Rev 2013, 12:875-884.
5. Filosso P.L., Galassi C., Ruffini E., Margaritora S., Bertolaccini L., Casadio C., et al. Thymoma and the increased risk of developing extrathymic malignancies: a multicentre study. Eur J Cardiothorac Surg 2013, 44:219-224.
6. Savino W., Manganella G., Verley J.M., Wolff A., Berrih S., Levasseur P., et al. Thymoma epithelial cells secrete thymic hormone but do not express class II antigens of the major histocompatibility complex. JClin Invest 1985, 76:1140-1146.
7. Scarpino S., Di Napoli A., Stoppacciaro A., Antonelli M., Pilozzi E., Chiarle R., et al. Expression of autoimmune regulator gene (AIRE) and T regulatory cells in human thymomas. Clin Exp Immunol 2007, 149:504-512.
8. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
9. Giraud M., Taubert R., Vandiedonck C., Ke X., Levi-Strauss M., Pagani F., et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007, 448:934-937.
10. Strobel P., Rosenwald A., Beyersdorf N., Kerkau T., Elert O., Murumagi A., et al. Selective loss of regulatory T cells in thymomas. Ann Neurol 2004, 56:901-904.
11. Romi F., Skeie G.O., Aarli J.A., Gilhus N.E. Muscle autoantibodies in subgroups of myasthenia gravis patients. JNeurol 2000, 247:369-375.
12. Meager A., Wadhwa M., Dilger P., Bird C., Thorpe R., Newsom-Davis J., et al. Anti-cytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis. Clin Exp Immunol 2003, 132:128-136.
13. Slavikova M., Schmeisser H., Kontsekova E., Mateicka F., Borecky L., Kontsek P. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia. JInterferon Cytokine Res 2003, 23:143-147.
14. Rudick R.A., Simonian N.A., Alam J.A., Campion M., Scaramucci J.O., Jones W., et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998, 50:1266-1272.
15. Ikeda Y., Toda G., Hashimoto N., Umeda N., Miyake K., Yamanaka M., et al. Naturally occurring anti-interferon-alpha 2a antibodies in patients with acute viral hepatitis. Clin Exp Immunol 1991, 85:80-84.
16. Savino W. The thymus is a common target organ in infectious diseases. PLoS Path 2006, 2:e62.
17. Cufi P., Dragin N., Weiss J.M., Martinez-Martinez P., De Baets M.H., Roussin R., et al. Implication of double-stranded RNA signaling in the etiology of autoimmune myasthenia gravis. Ann Neurol 2013, 73:281-293.
18. Suster S., Moran C.A. Thymoma classification: current status and future trends. Am J Clin Pathol 2006, 125:542-554.
19. Le Panse R., Berrih Aknin S. Thymic myoid cells protect thymocytes from apoptosis and modulate their differentiation: implication of the ERK and Akt signaling pathways. Cell Death Differ 2005, 12:463-472.
20. Moreau F., Fetouchi R., Micalessi I., Brejeon V., Bacon N., Jannes G., et al. Detection and genotyping of human papillomavirus by real-time PCR assay. JClin Virol 2013, 56:244-249.
21. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., et al. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int Immunol 2003, 15:903-913.
22. Takeuchi O., Akira S. Pattern recognition receptors and inflammation. Cell 2010, 140:805-820.
23. Bernasconi P., Barberis M., Baggi F., Passerini L., Cannone M., Arnoldi E., et al. Increased toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. Am J Pathol 2005, 167:129-139.
24. Harvey M., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A., Donehower L.A. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet 1993, 5:225-229.
25. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253:49-53.
26. Marques J.T., Rebouillat D., Ramana C.V., Murakami J., Hill J.E., Gudkov A., et al. Down-regulation of p53 by double-stranded RNA modulates the antiviral response. JVirol 2005, 79:11105-11114.
27. Hirabayashi H., Fujii Y., Sakaguchi M., Tanaka H., Yoon H.E., Komoto Y., et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997, 73:639-644.
28. Yoshikawa H., Sato K., Edahiro S., Furukawa Y., Maruta T., Iwasa K., et al. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. JNeuroimmunol 2006, 175:169-175.
29. Meager A., Visvalingam K., Peterson P., Moll K., Murumagi A., Krohn K., et al. Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1. PLoS Med 2006, 3:e289.
30. Willcox N., Leite M.I., Kadota Y., Jones M., Meager A., Subrahmanyam P., et al. Autoimmunizing mechanisms in thymoma and thymus. Ann N Y Acad Sci 2008, 1132:163-173.
31. Cufi P., Dragin N., Ruhlmann N., Weiss J.M., Fadel E., Serraf A., et al. Central role of interferon-beta in thymic events leading to myasthenia gravis. JAutoimmun 2014, 52:44-52.
32. Lamken P., Lata S., Gavutis M., Piehler J. Ligand-induced assembling of the type I interferon receptor on supported lipid bilayers. JMol Biol 2004, 341:303-318.
33. Jaks E., Gavutis M., Uze G., Martal J., Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. JMol Biol 2007, 366:525-539.
34. Piehler J., Schreiber G. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2. JMol Biol 1999, 294:223-237.
35. Yamamoto S., Yano H., Sanou O., Ikegami H., Kurimoto M., Kojiro M. Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8. Hepatol Res off J Jpn Soc Hepatol 2002, 24:99.
36. Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., et al. Different relative activities of human cell-derived interferon-alpha subtypes: IFN-alpha 8 has very high antiviral potency. JInterferon Cytokine Res 1996, 16:1027-1033.
37. Zandberg D.P., Bhargava R., Badin S., Cullen K.J. The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 2013, 63:57-81.
38. zur Hausen H., de Villiers E.M. Human papillomaviruses. Annu Rev Microbiol 1994, 48:427-447.
39. Sano T., Oyama T., Kashiwabara K., Fukuda T., Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998, 153:1741-1748.
40. Laster A.J., Itoh T., Palker T.J., Haynes B.F. The human thymic microenvironment: thymic epithelium contains specific keratins associated with early and late stages of epidermal keratinocyte maturation. Differentiation 1986, 31:67-77.
41. DeCarlo C.A., Rosa B., Jackson R., Niccoli S., Escott N.G., Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol 2012, 2012:785825.
42. Daud, Scott M.E., Ma Y., Shiboski S., Farhat S., Moscicki A.B. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer 2011, 128:879-886.
43. Alexander R.E., Davidson D.D., Lopez-Beltran A., Montironi R., Maclennan G.T., Comperat E., et al. Human papillomavirus is not an etiologic agent of urothelial inverted papillomas. Am J Surg Pathol 2013, 37:1223-1228.
44. Steinestel J., Cronauer M.V., Muller J., Al Ghazal A., Skowronek P., Arndt A., et al. Overexpression of p16(INK4a) in urothelial carcinoma in Situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection. PloS One 2013, 8:e65189.
45. Cavalcante P., Serafini B., Rosicarelli B., Maggi L., Barberis M., Antozzi C., et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010, 67:726-738.
46. Csuka D., Banati M., Rozsa C., Fust G., Illes Z. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012, 19:842-846.
47. Valentin H., Azocar O., Horvat B., Williems R., Garrone R., Evlashev A., et al. Measles virus infection induces terminal differentiation of human thymic epithelial cells. JVirol 1999, 73:2212-2221.
48. Vidalain P.O., Laine D., Zaffran Y., Azocar O., Servet-Delprat C., Wild T.F., et al. Interferons mediate terminal differentiation of human cortical thymic epithelial cells. JVirol 2002, 76:6415-6424.
49. Arimori S., Ichimura K., Tokunaga M., Morita K. Retrovirus-like particles in human thymomas. Tokai J Exp Clin Med 1990, 15:219-225.